Synonyms: ErbB-3, HER3
Seribantumab (Anti-ERBB3 / HER3) is a fully human IgG2 monoclonal antibody that targets HER3. It inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models. MW : 143.14 KD.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Name | Citation | HER2 | Others |
|---|---|---|---|
| Canertinib (CI-1033) | 51 | EGFR | |
| CP-724714 | 109 | ||
| Sapitinib (AZD8931) | 50 | ErbB3,EGFR | |
| CUDC-101 | 23 | EGFR,HDAC,HDAC1 | |
| Mubritinib (TAK 165) | 41 | ||
| AEE788 (NVP-AEE788) | 16 | EGFR,c-Abl,FLT1 | |
| AC480 (BMS-599626) | 12 | HER1,HER4 | |
| TAK-285 | 5 | EGFR/HER1,HER4,MEK1 | |
| Tyrphostin AG 879 | 3 | Trk | |
| Tuxobertinib (BDTX-189) | 3 | EGFR,RIPK2,BLK | |
| Epertinib hydrochloride | 1 | EGFR,HER4 | |
| TAS0728 | 1 | ||
| Tyrphostin AG-528 | 0 | EGFR | |
| SU5204 | 1 | VEGFR-2 | |
| Pyrotinib dimaleate | 6 | EGFR | |
| Poziotinib (NOV120101, HM781-36B) | 37 | HER1,HER4 | |
| HER2-Inhibitor-1 | 1 | ||
| Zongertinib (BI 1810631) | 1 | EGFR-Ex20ins | |
| Nordihydroguaiaretic acid (NDGA) | 2 | p300,IGF-1R,lipoxygenase | |
| EGCG ((-)-Epigallocatechin Gallate) | 42 | FASN,EGFR,DNMT |
| Description |
Seribantumab (Anti-ERBB3 / HER3) is a fully human IgG2 monoclonal antibody that targets HER3. It inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models. MW : 143.14 KD.
|
References |
|---|
| CAS No. | 1334296-12-6 |
|---|---|
| Molecular Weight | 143.14 |
| Isotype | Human IgG2SA |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT06731907 | RECRUITING | Drug: Carboplatin|Drug: Paclitaxel|Drug: Nab-paclitaxel|Drug | Non-small Cell Lung Cancer | Merck Sharp & Dohme LLC | 2025-03-30 | PHASE2 |
| NCT04165070 | RECRUITING | Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed | Carcinoma, Non-Small-Cell Lung | Merck Sharp & Dohme LLC | 2019-12-19 | PHASE1; PHASE2 |
| NCT05919537 | ACTIVE_NOT_RECRUITING | Drug: HMBD-001|Drug: Docetaxel|Drug: Nab-paclitaxel|Drug: Ge | Non-Small Cell Lung Cancer; Pancreatic Cancer; Locally Advanced Solid Tumor; Metastatic Solid Tumor | Hummingbird Bioscience | 2023-09-06 | PHASE1 |
| NCT07701941 | NOT_YET_RECRUITING | Drug: Patritumab deruxtecan|Drug: Trastuzumab deruxtecan | Hormone Receptor Positive; HER2-low or HER2-ultralow; Unresectable or Metastatic Breast Cancer | Daiichi Sankyo | 2026-08-03 | PHASE1; PHASE2 |
| NCT05142189 | RECRUITING | Drug: Docetaxel|Drug: Carboplatin|Drug: Paclitaxel | Non-Small Cell Lung Cancer | BioNTech SE | 2022-06-17 | PHASE1 |
| NCT07193394 | RECRUITING | Drug: Tucatinib (ONT-380)|Drug: Trastuzumab (Herceptin) | Metastatic Breast Cancer ( HER2 Negative); Unresectable Breast Cancer | Institut Curie | 2026-01-31 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-08-18)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.